| Symbol
| G6PD
| contributors: mct - updated : 05-05-2020
|
| HGNC name
| glucose-6-phosphate dehydrogenase
|
| HGNC id
| 4057
|
| corresponding disease(s)
|
G6PDD
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
|
is a poor prognostic factor in bladder cancer, and the levels of G6PD expression increase with increasing tumor stage  | | constitutional
|
|
|
| loss of function
| |
significant age-dependent decrease in G6PD activity | | constitutional
|
|
|
| gain of function
| |
restores redox balance in endothelial cells exposed to high glucose, which is a potentially important therapeutic target to protect ECs from the deleterious effects of high glucose | | constitutional
|
|
|
| gain of function
| |
up-regulation of G6PD in pancreatic beta-cells would induce beta-cell dysregulation through ROS accumulation in the development of type 2 diabetes | |
Variant & Polymorphism
| 
| |
Candidate gene
| Marker
| G6PD may be a novel predictive prognostic marker for lung adenocarcinoma | Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| immunology | infectious | | |
| regulation of macrophages via modulation of G6PDH activity appears to provide a novel window for those seeking to develop alternative therapies for the treatment of leishmaniasis | | cancer | urinary | | |
| 6-aminonicotinamide (6-AN), a competitive G6PD inhibitor, may be a potential therapy for bladder cancer, particularly in cases with high G6PD expression | | neurology | acquired | | |
| G6PD may be considered as potential therapeutic target for treatment of ischemic brain injury | | cancer | digestive | colon | |
| PAK4 and/or G6PD blockage might be a potential therapeutic strategy for colon cancer |
| | |
|
| G6pd-deficient mice had smaller islets and impaired glucose tolerance compared with control mice, which suggests that G6pd deficiency per se leads to beta-cell dysfunction and death |